002198.SHE Guangdong Jiaying Pharmaceutical Co Ltd
- Market cap
- CNY 1.60B
- P/E
- 158.0x
- P/B
- 2.16x
- ROE
- 0.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002198.SHE undervalued?
Graham numberThe Graham number of Guangdong Jiaying Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong Jiaying Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guangdong Jiaying Pharmaceutical Co Ltd yet.
Guangdong Jiaying Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong Jiaying Pharmaceutical Co Ltd
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat ailments, colds, orthopedics, rheumatism, gynecology, hepatobiliary diseases, tonics, and gastrointestinal disorders. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablets (capsules), Xiaoyan Lidan Tablets, and Jinju Wuhua tea, e…
Full company profileGuangdong Jiaying Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong Jiaying Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 450M | 468M | 537M | 501M | 545M | 575M | 659M | 533M | 376M | 384M | 361M |
| Gross Profit | 344M | 342M | 392M | 393M | 397M | 431M | 430M | 347M | 224M | 230M | 204M |
| Operating Income | 66.7M | -207M | 41.8M | -114M | 24.1M | 5.38M | 53.9M | 40.5M | 25.3M | 44.7M | 15.8M |
| EBITDA | 93.9M | -177M | 71.3M | -83.5M | 55.3M | 35.3M | 77.5M | 63.6M | 44.7M | 59.4M | 4.61M |
| Net Income | 55.2M | -215M | 35.9M | -122M | 19.8M | 1.48M | 43.9M | 34.3M | 20.6M | 30.5M | 2.31M |
| EPS | 0.11 | -0.42 | 0.07 | -0.24 | 0.04 | 0.00 | 0.09 | 0.07 | 0.04 | 0.06 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.10B | 877M | 890M | 856M | 808M | 807M | 847M | 848M | 839M | 849M | 851M |
| Total Liabilities | 114M | 127M | 104M | 193M | 125M | 123M | 118M | 84.6M | 80.6M | 131M | 132M |
| Shareholders' Equity | 985M | 750M | 785M | 663M | 683M | 684M | 728M | 763M | 758M | 718M | 720M |
| Cash & Short-term Investments | 73.3M | 82.0M | 115M | 122M | 142M | 239M | 234M | 334M | 336M | 165M | 119M |
| Total Debt | 19.9M | 40.0M | 19.0M | 96.8M | 20.2M | 31.1M | 5.77M | 4.37M | 3.33M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 53.1M | 30.6M | 62.1M | 13.0M | 96.9M | 51.8M | 27.2M | 98.5M | 60.8M | 9.00M | - |
| Capital Expenditure | 12.0M | 18.4M | 8.95M | 18.8M | 11.7M | 2.34M | 2.74M | 5.06M | 38.7M | 110M | 30.1M |
| Free Cash Flow | 41.1M | 12.2M | 53.2M | -5.85M | 85.2M | 49.5M | 24.4M | 93.4M | 22.1M | -101M | -97.5M |
| Ratios | |||||||||||
| ROE | 5.6% | -28.6% | 4.6% | -18.4% | 2.9% | 0.2% | 6.0% | 4.5% | 2.7% | 4.2% | 0.3% |
| ROA | 5.0% | -24.5% | 4.0% | -14.3% | 2.5% | 0.2% | 5.2% | 4.0% | 2.5% | 3.6% | 0.3% |
| Net Profit Margin | 12.3% | -45.9% | 6.7% | -24.4% | 3.6% | 0.3% | 6.7% | 6.4% | 5.5% | 7.9% | 0.6% |
| Debt to Equity | 0.02x | 0.05x | 0.02x | 0.15x | 0.03x | 0.05x | 0.01x | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangdong Jiaying Pharmaceutical Co Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 21, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 25.4M | 0.05 | 123.2% |
| 2023 | CNY 445.00 | 0.00 | 0.0% |
| 2022 | CNY 454K | 0.00 | 1.0% |
| 2021 | CNY 1.02M | 0.00 | 68.9% |
| 2020 | CNY 3.80M | 0.01 | 19.1% |
| 2019 | CNY 3.45M | 0.01 | - |
| 2018 | CNY 1.33M | 0.00 | 3.7% |
| 2017 | CNY 21.9M | 0.04 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Apr 3, 2014.
Who owns Guangdong Jiaying Pharmaceutical Co Ltd
- Insiders 24.50%
- Institutions 0.89%
- Public & others 74.61%
- Shares outstanding 508M
- Free float 412M
Guangdong Jiaying Pharmaceutical Co Ltd company profile
- Company name
- Guangdong Jiaying Pharmaceutical Co Ltd
- Ticker
- 002198.SHE
- ISIN
- CNE1000008P1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 18, 2007
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 594
- Fiscal year end
- December
- Address
- Area B , Dongsheng Industrial Park, Meizhou, China, 514071
- Phone
- 86 75 3613 3081
- Website
- gdjyzy.com.cn
About Guangdong Jiaying Pharmaceutical Co Ltd
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat ailments, colds, orthopedics, rheumatism, gynecology, hepatobiliary diseases, tonics, and gastrointestinal disorders. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablets (capsules), Xiaoyan Lidan Tablets, and Jinju Wuhua tea, etc., as well as double throat lozenges and tablets, heavy psychotherapy, Yuqiao detoxification granules, orange peel cough granules, bone-setting Qili tablets and capsules, anti-inflammatory and choleretic tablets, chrysanthemum five-flower tea granules, Zhuang Yao Jian Shen pills, Gujing Shenrong pills, Guifuli Zhongwan, and stomach pain tablets. Guangdong Jiaying Pharmaceutical Co., Ltd. was founded in 2003 and is based in Meizhou, China.
Guangdong Jiaying Pharmaceutical Co Ltd management
2- Mr. Yong Ping YouGM & Director · born 1981
- Mr. Jun SunDeputy GM & Secretary to the Board · born 1986